arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cellectar Biosciences, Inc.

CLRB
$2.24 ▼ -0.12 (-5.08%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
75 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cellectar Biosciences, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $27.4M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -19.0%
FCF / Share $-0.49
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-5.65M
↑ +14.4%
FCF / Share Free cash flow per share
$-0.49
↑ +57.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 24 years · 75 quarters